Sign In
Buy EVFM
$0.0070
-0.0001 (-1.41%)
At Close: Jul 31, 2026
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
04:36pm, Thursday, 14'th Nov 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
08:00am, Wednesday, 06'th Nov 2024
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholder
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
07:00am, Wednesday, 14'th Aug 2024
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
09:00am, Thursday, 25'th Jul 2024
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
08:47am, Tuesday, 23'rd Jul 2024
— Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024 — — UAE contraceptive drug market is projected to reach $185.1 million by 203
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
07:20am, Monday, 15'th Jul 2024
MUMBAI, India and NAPLES, Fla. and SAN DIEGO , July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced toda
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
08:36am, Thursday, 27'th Jun 2024
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for mil
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
08:36am, Tuesday, 11'th Jun 2024
-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Ph
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
06:50am, Wednesday, 15'th May 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Com
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
08:36am, Thursday, 18'th Apr 2024
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the U
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
08:36am, Wednesday, 27'th Mar 2024
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourt
-- New weight loss drugs like Ozempic, Wegovy and Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO , March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonis
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
08:00am, Thursday, 01'st Feb 2024
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO , Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosc
